Health care stocks were decreasing late Wednesday afternoon, with the NYSE Health Care Index down 0.2% and the Health Care Select Sector SPDR Fund (XLV) easing 0.1%.
The iShares Biotechnology ETF (IBB) rose 0.4%.
In sector news, US Secretary of Health and Human Services Robert Kennedy Jr. is weighing a proposal for a key government vaccine advisory panel to scrutinize vaccines with aluminum ingredients, Bloomberg reported. A review could impact at least two dozen vaccines, the report said.
In corporate news, Zoetis (ZTS) shares were falling 3.7% after Stifel downgraded the stock to hold from buy and cut its price target to $160 from $165.
Gilead Sciences (GILD) shares added 0.3% after the drugmaker said the US Food and Drug Administration has approved its Yeztugo, its twice-yearly injectable for HIV prevention.
Caris Life Sciences (CAI) shares surged 23% in their Nasdaq debut Wednesday after the company priced its IPO of 23.5 million shares at $21 each.
Grail (GRAL) shares jumped 13% after the firm said it has seen better cancer detection results from an analysis of the first 25,578 participants in its Pathfinder 2 study, compared with the previous Pathfinder study.
Maia Biotechnology (MAIA) shares popped 9% after the company said it has signed a clinical master supply agreement with Roche
for hard-to-treat cancer therapies.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。